Jump Financial LLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 394.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,776 shares of the biopharmaceutical company’s stock after buying an additional 23,748 shares during the period. Jump Financial LLC’s holdings in Alnylam Pharmaceuticals were worth $5,965,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1.2% during the first quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock worth $1,768,291,000 after buying an additional 126,373 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Alnylam Pharmaceuticals by 9.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,074,144 shares of the biopharmaceutical company’s stock worth $968,221,000 after purchasing an additional 353,538 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in Alnylam Pharmaceuticals by 0.3% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,202,793 shares of the biopharmaceutical company’s stock worth $761,144,000 after purchasing an additional 10,609 shares during the period. State Street Corp lifted its position in Alnylam Pharmaceuticals by 2.1% in the first quarter. State Street Corp now owns 2,909,490 shares of the biopharmaceutical company’s stock worth $475,091,000 after purchasing an additional 59,101 shares during the period. Finally, Geode Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 5.7% in the fourth quarter. Geode Capital Management LLC now owns 1,689,929 shares of the biopharmaceutical company’s stock worth $401,144,000 after purchasing an additional 90,455 shares during the period. 94.43% of the stock is currently owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Stock Performance
Shares of NASDAQ ALNY traded up $4.42 during mid-day trading on Friday, reaching $199.29. The company had a trading volume of 338,353 shares, compared to its average volume of 710,146. Alnylam Pharmaceuticals, Inc. has a twelve month low of $138.18 and a twelve month high of $242.97. The stock has a market capitalization of $24.82 billion, a PE ratio of -22.79 and a beta of 0.48. The stock’s 50 day moving average is $194.83 and its 200-day moving average is $202.94.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.57. Alnylam Pharmaceuticals had a negative net margin of 93.13% and a negative return on equity of 1,287.80%. The business had revenue of $319.29 million for the quarter, compared to the consensus estimate of $312.53 million. During the same period in the prior year, the business posted ($2.00) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 49.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.45 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on ALNY shares. HC Wainwright cut their target price on Alnylam Pharmaceuticals from $415.00 to $405.00 and set a “buy” rating for the company in a research report on Tuesday. Morgan Stanley upped their target price on Alnylam Pharmaceuticals from $205.00 to $210.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 4th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday. BMO Capital Markets upgraded Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $200.00 to $250.00 in a research report on Friday, May 5th. Finally, Sumitomo Mitsui Financial Group started coverage on Alnylam Pharmaceuticals in a report on Wednesday, April 26th. They issued a “neutral” rating and a $220.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
Featured Articles
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alnylam Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Alnylam Pharmaceuticals wasn’t on the list.
While Alnylam Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
